MLH1 and cancer: This population is heterogeneous, encompassing special cases of Lynch syndrome resulting from hypermethylation of the MLH1 promoter BRAF V600E somatic mutation that is considered sporadic cancer, and “Lynch-like syndrome (LLS)” if the previous two alterations are absent [18,19].